Download presentation
Presentation is loading. Please wait.
1
The Acne Landscape Is Evolving
2
This program will include a discussion of data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.
3
Background
4
Treatment for Acne Is Growing
5
Psychosocial and QoL Impact of Patients With Acne
6
Severity of Acne and Impact on Patients
7
Determining Acne Severity
8
Guideline Recommended Treatments for Moderate to Severe Acne
9
Individualizing Treatment for Patients With Moderate to Severe Acne
10
Tips to Increase Adherence to Acne Treatment
11
New Topical Retinoid Tretinoin 0.05% Lotion
12
Evaluating Patient Satisfaction
13
Results Tretinoin 0.05% Lotion
14
Relevance to Clinical Practice
15
New Topical Antibiotic 4% Minocycline Foam
16
Efficacy 4% Minocycline Foam Absolute Change in Inflammatory Lesion Count at Week 12
17
Efficacy 4% Minocycline Foam Proportion of Patients Achieving IGA = Clear/Almost Clear
18
Safety Minocycline 4% Foam
19
New Retinoid With a New MOA Trifarotene 50 μg/g Cream
20
PERFECT 1 and 2 Efficacy Endpoints Trifarotene 50 μg/g Cream
21
Results: Facial IGA and Truncal PGA Trifarotene 50 μg/g Cream
22
Safety Trifarotene 50 μg/g Cream
23
New Topical Anti-Androgen Clascoterone 1% Cream
24
Phase 3 Baseline Lesion Counts & IGA Scores Clascoterone 1% Cream
25
Phase 3 Efficacy Results Clascoterone 1% Cream
26
Clascoterone, 1% Cream Acne Phase 3 Studies IGA Treatment Success at Week 12: IGA (0) or (1)
27
Clascoterone, 1% Cream: Phase 3 Studies Absolute Reduction of Non-Inflammatory Lesion Count Week 12
28
New Oral Antibiotic Sarecycline
29
Phase 3 Study Design Sarecycline
30
Efficacy Sarecycline
31
Safety Sarecycline
32
Which Patients Are Good Candidates for These Medications?
33
Concluding Remarks
34
Abbreviations
Similar presentations
© 2025 SlidePlayer.com. Inc.
All rights reserved.